1. Opening Hook
On World Science Day, Dr. Bhaskara Rao didn’t just talk about science — he gave investors a crash course in optimism. KIMS pulled a Houdini: 23% revenue growth in what’s usually a dull quarter, but profit vanished like the last dose of antibiotics. Between new hospitals still learning to crawl and old ones stretching to run, management insists all’s “under control.” But as bed counts swell faster than margins, one wonders — is it expansion, or just expensive ambition in disguise?
Stay hooked — things get surgical later.
2. At a Glance
- Revenue up 23.3%: CFO swears it’s “real growth,” not accounting anesthesia.
- EBITDA down 6.7%: Expansion hangover hits the P&L harder than expected.
- EBITDA Margin at 21.6% (vs 28.5% YoY): That’s what “new hospital smell” costs.
- PAT down 40%: Profit caught the flu; recovery expected post new-hospital fever.
- Cash ₹120 crore: Just enough to pay the expansion bill and a few prayers.
- EPS down 37.7%: Earnings took a sabbatical to Thane and Mahadevapura.
3. Management’s Key Commentary
Dr. Bhaskara Rao: “Results are good despite Q2 being dull.”
(Translation: Mediocre is the new excellent when you’re commissioning hospitals.)
Abhinay Bollineni: “EBITDA dip is due to 4-5 new hospitals yet to break even.”
(Translation: Growth pains, literally — new units are the toddlers of the balance sheet 😏*)
CFO Sachin Salvi: “We won’t compromise on quality; margins are cluster-specific.”
(Translation: Margins may bleed, but at least the surgeries won’t.)
Dr. Rao: “We’re investing in AI and robotics to improve patient recovery.”
(Translation: When margins fall, invoke technology. Works every quarter.*)
Abhinay Bollineni: “Thane to break even in 2 months; Bangalore in 12.”
(Translation: One’s sprinting, the other’s still finding its running shoes.*)
Sreenath Reddy: “Competition in Bangalore is strong, but we’ve got the right locations.”
(Translation: Hope and geography — the twin pillars of strategy 🤞*)
Abhinay Bollineni: “We prefer
